 |
 |
 |
 |
 |
 |
 |
 |
|
||||||||
|
SELECT PUBLICATIONS
Coiffier B et al. Long-term results of the GELA study comparing R-CHOP and CHOP
chemotherapy in older patients with diffuse large B-cell lymphoma show good survival
in poor-risk patients.
Proc ASCO 2007;Abstract 8009.
Forstpointner R et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide,mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2004;104(10):3064-71. Abstract
Habermann TM et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006;24(19):3121- 7. Abstract
Hiddemann W et al. Rituximab maintenance prolongs response duration after salvage
therapy with R-FCM in patients with relapsed follicular lymphomas and mantle cell
lymphomas: Results of a prospective randomized trial of the German Low Grade
Lymphoma Study Group (GLSG).
Proc ASH 2005;Abstract 920.
Morrison VA et al. Maintenance rituximab (MR) compared to observation (OBS) after R-CHOP or CHOP in older patients (pts) with diffuse large B-cell lymphoma (DLBCL): An Intergroup E4494/C9793 update. Proc ASCO 2007; Abstract 8011
Pfreundschuh M et al. Six vs eight cycles of bi-weekly CHOP-14 with or without rituximab for elderly patients with diffuse large B-cell lymphoma (DLBCL): Results of the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Proc ASH 2006; Abstract 205.
Pfreundschuh M et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: Results of the NHL-B1 trial of the DSHNHL. Blood 2004;104(3):626-33. Abstract
Portlock CS et al. The NHL-15 protocol for aggressive non-Hodgkin’s lymphoma: A sequential dose-dense, dose-intense regimen of doxorubicin, vincristine and high-dose cyclophosphamide. Ann Oncol 2004;15(10):1495-503. Abstract
Van Oers MH et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: Results of a prospective randomized phase 3 intergroup trial. Blood 2006;108(10):3295-301. Abstract
| Table of Contents | Top of Page |
